Aerosol Delivery with Two Nebulizers Through High-Flow Nasal Cannula: A Randomized Cross-Over Single-Photon Emission Computed Tomography-Computed Tomography Study
Authors:
- Jonathan DugernierJDJonathan Dugernier
- Thibaud JumetzTJThibaud Jumetz
- 1 October 2017
- journal article
- research article
- Published by SAGE Publications in Journal of Aerosol Medicine and Pulmonary Drug Delivery
- Vol. 30 (5) , 349-358
Abstract
Background: High-flow nasal cannula use is developing in ICUs. The aim of this study was to compare aerosol efficiency by using two nebulizers through a high-flow nasal cannula: the most commonly used jet nebulizer (JN) and a more efficient vibrating-mesh nebulizer (VN). Methods: Aerosol delivery of diethylenetriaminepentaacetic acid labeled with technetium-99m (4 mCi/4 mL) to the lungs by using a VN (Aerogen Solo®; Aerogen Ltd., Galway, Ireland) and a constant-output JN (Opti-Mist Plus Nebulizer®; ConvaTec, Bridgewater, NJ) through a high-flow nasal cannula (Optiflow®; Fisher & Paykel, New Zealand) was compared in six healthy subjects. Flow rate was set at 30 L/min through the heated humidified circuit. Pulmonary and extrapulmonary deposition was measured by single-photon emission computed tomography combined with a low-dose computed tomographic scan and by planar scintigraphy. Results: Lung deposition was only 3.6 (2.1–4.4) and 1 (0.7–2)% of the nominal dose with the VN and the JN, respectively (p < 0.05). The JN showed higher retained doses than the VN. However, both nebulizers were associated with substantial deposition in the single limb circuit, the humidification chamber, and the nasal cannula [58.2 (51.6–61.6)% of the nominal dose with the VN versus 19.2 (15.8–22.9)% of the nominal dose with the JN, p < 0.05] and in the upper respiratory tract [17.6 (13.4–27.9)% of the nominal dose with the VN and 8.6 (6.0–11.0)% of the nominal dose with the JN, p < 0.05], especially in the nasal cavity. Conclusions: In the specific conditions of the study, pulmonary drug delivery through the high-flow nasal cannula is about 1%–4% of the initial amount of drugs placed in the nebulizer, despite the higher efficiency of the VN as compared with the JN.Keywords
This publication has 46 references indexed in Scilit:
- Standardization of Techniques for Using Single-Photon Emission Computed Tomography (SPECT) for Aerosol Deposition Assessment of Orally Inhaled ProductsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2012
- A Comparison of Amount and Speed of Deposition Between the PARI LC STAR ® Jet Nebulizer and an Investigational eFlow ® NebulizerJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2011
- Aerosol drug delivery: developments in device design and clinical useThe Lancet, 2011
- Mode of Breathing—Tidal or Slow and Deep—through the I-neb Adaptive Aerosol Delivery (AAD) System Affects Lung Deposition of 99m Tc-DTPAJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Lung Deposition of BDP/Formoterol HFA pMDI in Healthy Volunteers, Asthmatic, and COPD PatientsJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2010
- Lung deposition of inhaled α1-proteinase inhibitor in cystic fibrosis and α1-antitrypsin deficiencyEuropean Respiratory Journal, 2009
- Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: A pilot projectPediatric Pulmonology, 2008
- Aerosol Delivery through Nasal Cannulas: An In Vitro StudyJournal of Aerosol Medicine and Pulmonary Drug Delivery, 2008
- Comparison of drug delivery from conventional versus "Venturi" nebulizersEuropean Respiratory Journal, 1997
- Validation of respiratory inductance plethysmography (“Respitrace”®) for the measurement of tidal breathing parameters in newbornsPediatric Pulmonology, 1992